DIO TREE

DIO TREE Overview

Dio Tree develops a novel small molecule for the treatment of ovarian cancer. The technology is based on inhibition of the enzyme DIO3, which is a major driver in many types of cancer, specifically ovarian cancer. The technology involves a series of small molecules targeting DIO3.

Cumulative Funding Raised Over Time ($)

Latest News

Aug 10, 2023 · www.calcalistech.com

growth-positive

"Imagine a scenario where a single drug could alter the course of a patient's battle with cancer" | CTech

Dio Tree, a company developing a new drug to treat ovarian cancer, has raised $400,000 in a seed funding round. The investment was led by the Israeli Innovation Authority and NGT fund. The company, which currently has three employees, plans to use the funds primarily for research and development. The drug, which is still in the research and development phase, could potentially be expanded to treat other types of cancer, including breast, lung, and pancreas. Clinical trials are expected to begin within two years, with the treatment potentially available to the public in about five years.

Investment

Funding

Team Members

3

Employees: 1-10

Web & Social Links

Locations

Wadi el-Haj St 13, Nazareth, Israel

Photos & Videos

No files yet

DIO TREE Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info